- HK$127.54m
- HK$485.93m
- HK$336.11m
Brief: Purapharm Corp Sees Net Profit Of About HK$10 MLN For HY
Brief: PuraPharm Corp Posts Net Loss For Year Of HK$227.3 Mln
Brief: Purapharm Corp Says Guangxi Zhuang Autonomous Region FDA Approved Application For Unit To Manufacture Qing Fei Pai Du Tang Granule
Brief: Purapharm Calrifies on Rumors Regarding Disruption And Suspension Of Production Facilities
Brief: Purapharm Corp Expects Group To Record Net Loss Of At Least HK$140 Mln For FY2019
HK-listed PuraPharm sinks to record low on share sale at discount
Brief: Purapharm Corp Ltd Announces Proposed Rights Issue
Brief: Purapharm Expects Group's Revenue For HY Will Record Decrease Of About 15%
Brief: Purapharm Corp Entered Into Loan Capitalisation Agreement
Brief: Purapharm Sees FY Net Profit Of More Than Hk$15 Mln
Brief: Purapharm Corp Says Lau Ka Kuen Appointed As CFO
Brief: PuraPharm Corp Posts HY Profit Attributable HK$13.3 Mln
Brief: Purapharm Corp Expects Both HY Revenue And Profit To Increase
Brief: PuraPharm Corp Says Chan Lung Sang Retires As An Executive Director
Brief: Purapharm Corp Posts FY Revenue HK$591.6 Mln
Brief: Purapharm Corp Says FY Profit May Fall More Than 90%
Brief: Purapharm Corp re-designates Chan Kin Man, Eddie to executive director
Brief: Purapharm Corp says HY revenue HK$263.1 million
Brief: PuraPharm Corp says unit entered into share purchase agreements